We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 03, 2022

Prognostic Value of Lymph Node Staging With PSMA PET/CT and Extended PLND in Patients With Node-Positive Prostate Cancer

BJU International

 

Additional Info

Disclosure statements are available on the authors' profiles:

BJU International
The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer
BJU Int 2022 Sep 07;[EPub Ahead of Print], D Meijer, RH Ettema, PJ van Leeuwen, TH van der Kwast, HG van der Poel, ML Donswijk, DE Oprea-Lager, EM Bekers, AN Vis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading